
NAMS Valuation
NewAmsterdam Pharma Company NV
- Overview
- Forecast
- Valuation
- Earnings
NAMS Relative Valuation
NAMS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NAMS is overvalued; if below, it's undervalued.
Historical Valuation
NewAmsterdam Pharma Company NV (NAMS) is now in the Fair zone, suggesting that its current forward PS ratio of 148.69 is considered Fairly compared with the five-year average of 3.23. The fair price of NewAmsterdam Pharma Company NV (NAMS) is between 3.53 to 85.52 according to relative valuation methord.
Relative Value
Fair Zone
3.53-85.52
Current Price:23.95
Fair
-11.70
PE
1Y
3Y
5Y
Trailing
Forward
-8.45
EV/EBITDA
NewAmsterdam Pharma Company NV. (NAMS) has a current EV/EBITDA of -8.45. The 5-year average EV/EBITDA is 3.15. The thresholds are as follows: Strongly Undervalued below -11.88, Undervalued between -11.88 and -4.36, Fairly Valued between 10.67 and -4.36, Overvalued between 10.67 and 18.18, and Strongly Overvalued above 18.18. The current Forward EV/EBITDA of -8.45 falls within the Undervalued range.
-7.23
EV/EBIT
NewAmsterdam Pharma Company NV. (NAMS) has a current EV/EBIT of -7.23. The 5-year average EV/EBIT is -4.21. The thresholds are as follows: Strongly Undervalued below -10.29, Undervalued between -10.29 and -7.25, Fairly Valued between -1.16 and -7.25, Overvalued between -1.16 and 1.88, and Strongly Overvalued above 1.88. The current Forward EV/EBIT of -7.23 falls within the Historic Trend Line -Fairly Valued range.
150.03
PS
NewAmsterdam Pharma Company NV. (NAMS) has a current PS of 150.03. The 5-year average PS is 160.41. The thresholds are as follows: Strongly Undervalued below -269.47, Undervalued between -269.47 and -54.53, Fairly Valued between 375.34 and -54.53, Overvalued between 375.34 and 590.28, and Strongly Overvalued above 590.28. The current Forward PS of 150.03 falls within the Historic Trend Line -Fairly Valued range.
-12.93
P/OCF
NewAmsterdam Pharma Company NV. (NAMS) has a current P/OCF of -12.93. The 5-year average P/OCF is -7.82. The thresholds are as follows: Strongly Undervalued below -19.00, Undervalued between -19.00 and -13.41, Fairly Valued between -2.22 and -13.41, Overvalued between -2.22 and 3.37, and Strongly Overvalued above 3.37. The current Forward P/OCF of -12.93 falls within the Historic Trend Line -Fairly Valued range.
-11.50
P/FCF
NewAmsterdam Pharma Company NV. (NAMS) has a current P/FCF of -11.50. The 5-year average P/FCF is -6.69. The thresholds are as follows: Strongly Undervalued below -15.68, Undervalued between -15.68 and -11.18, Fairly Valued between -2.20 and -11.18, Overvalued between -2.20 and 2.29, and Strongly Overvalued above 2.29. The current Forward P/FCF of -11.50 falls within the Undervalued range.
NewAmsterdam Pharma Company NV (NAMS) has a current Price-to-Book (P/B) ratio of 3.41. Compared to its 3-year average P/B ratio of 3.29 , the current P/B ratio is approximately 3.61% higher. Relative to its 5-year average P/B ratio of 0.43, the current P/B ratio is about 686.18% higher. NewAmsterdam Pharma Company NV (NAMS) has a Forward Free Cash Flow (FCF) yield of approximately -5.36%. Compared to its 3-year average FCF yield of -5.99%, the current FCF yield is approximately -10.60% lower. Relative to its 5-year average FCF yield of -5.99% , the current FCF yield is about -10.60% lower.
3.41
P/B
Median3y
3.29
Median5y
0.43
-5.31
FCF Yield
Median3y
-5.99
Median5y
-5.99
Competitors Valuation Multiple
The average P/S ratio for NAMS's competitors is 34.70, providing a benchmark for relative valuation. NewAmsterdam Pharma Company NV Corp (NAMS) exhibits a P/S ratio of 150.03, which is 332.40% above the industry average. Given its robust revenue growth of 112.56%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap

NAMS.O
NewAmsterdam Pharma Company NV
150.03
Average P/S: 34.70
112.56%
2.63B

OGN.N
Organon & Co
0.43
-6.72%
2.59B

LGND.O
Ligand Pharmaceuticals Inc
13.66
46.34%
2.60B

RARE.O
Ultragenyx Pharmaceutical Inc
3.78
27.99%
2.61B

MIRM.O
Mirum Pharmaceuticals Inc
5.59
61.20%
2.55B

CPRX.O
Catalyst Pharmaceuticals Inc
Loss
43.56%
2.54B
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NAMS increased by 36.80% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 1.40M to 2.98M.
The secondary factor is the P/E Change, contributed 4.41%to the performance.
Overall, the performance of NAMS in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch

CURB
Curbline Properties Corp.
23.370
USD
+2.23%

AMR
Alpha Metallurgical Resources Inc
125.780
USD
-6.35%

SBSW
Sibanye Stillwater Ltd
9.220
USD
-0.22%

EWTX
Edgewise Therapeutics Inc
14.260
USD
+0.99%

CAKE
Cheesecake Factory Inc
65.890
USD
+0.17%

HCM
HUTCHMED (China) Ltd
17.980
USD
+2.10%

SIG
Signet Jewelers Ltd
83.890
USD
-1.03%

CALX
Calix Inc
56.480
USD
+2.15%

NEOG
Neogen Corp
5.420
USD
+3.83%

FLYW
Flywire Corp
11.660
USD
-0.26%
FAQ

Is NewAmsterdam Pharma Company NV (NAMS) currently overvalued or undervalued?
NewAmsterdam Pharma Company NV (NAMS) is now in the Fair zone, suggesting that its current forward PS ratio of 148.69 is considered Fairly compared with the five-year average of 3.23. The fair price of NewAmsterdam Pharma Company NV (NAMS) is between 3.53 to 85.52 according to relative valuation methord.

What is NewAmsterdam Pharma Company NV (NAMS) fair value?

How does NAMS's valuation metrics compare to the industry average?

What is the current P/B ratio for NewAmsterdam Pharma Company NV (NAMS) as of Jul 29 2025?

What is the current FCF Yield for NewAmsterdam Pharma Company NV (NAMS) as of Jul 29 2025?

What is the current Forward P/E ratio for NewAmsterdam Pharma Company NV (NAMS) as of Jul 29 2025?
